Unlocking Value: A Strategic Acquisition for Pharmaceutical Innovation
Lisata Therapeutics Enters Acquisition Agreement with Kuva Labs
Lisata Therapeutics, publicly traded under NASDAQ:LSTA and FRA:8NE, has officially reached an agreement to be acquired by the privately held company, Kuva Labs Inc. The terms of the acquisition involve a cash payment of $4 per share to Lisata's shareholders. Additionally, shareholders will be eligible for a contingent value right (CVR) that could provide up to an extra $3.00 per share, contingent on the achievement of specific milestones related to drug development.
Kuva Acquisition Corp Initiates Tender Offer
Kuva Acquisition Corp, a wholly-owned subsidiary of Kuva Labs, formally launched a tender offer for Lisata Therapeutics' shares on June 10. The period for this tender offer is scheduled to conclude on July 10, 2026. This process allows Lisata's current shareholders to tender their shares as part of the acquisition.
Contingent Value Rights: Milestones for Additional Shareholder Returns
Shareholders participating in the tender offer will also receive a non-tradeable CVR. This CVR offers an initial payment of $1.25 per share upon the successful enrollment milestones for a Phase 2a glioblastoma trial of certepetide, Lisata's primary drug candidate. A further $1.75 per share will be disbursed if a New Drug Application (NDA) for certepetide is submitted or accepted for review by the relevant regulatory authorities, highlighting the performance-based nature of the acquisition's full value.
Board Recommendation and Financing Considerations
The board of directors at Lisata Therapeutics has unanimously endorsed the tender of shares by its stockholders, signaling their approval of the acquisition terms. Despite this, Kuva Labs has disclosed that it has not yet secured all necessary committed financing for the transaction. The company plans to fund the acquisition through a combination of debt, equity, or credit facilities, as it moves forward with its strategic plan.
Anticipated Completion and Delisting from Nasdaq
Following the successful tender of a majority of Lisata's shares, Kuva Labs will proceed to acquire any remaining shares through a subsequent merger, maintaining the same financial considerations for all shareholders. The entire transaction is projected to be finalized in the third quarter of 2026. Upon its completion, Lisata Therapeutics will be delisted from the Nasdaq Capital Market, marking its transition into a private entity under Kuva Labs' ownership.
